Holen Sie sich die Stockscreener-App
1.06
0.00%
0.00
Handel nachbörslich:
1.05
-0.01
-0.94%
Schlusskurs vom Vortag:
$1.06
Offen:
$1.08
24-Stunden-Volumen:
428.88K
Relative Volume:
0.61
Marktkapitalisierung:
$59.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.50M
KGV:
-1.4177
EPS:
-0.7477
Netto-Cashflow:
$-27.75M
1W Leistung:
+10.38%
1M Leistung:
+35.83%
6M Leistung:
+19.30%
1J Leistung:
-10.92%
1-Tages-Spanne:
$1.04
$1.11
1-Wochen-Bereich:
$0.9559
$1.11
52-Wochen-Spanne:
$0.5068
$1.915
Pds Biotechnology Corp Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corp
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
1.06 | 59.16M | 0 | -34.50M | -27.75M | -0.7477 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corp Aktie (PDSB) Neueste Nachrichten
PDS Biotech to Discuss First Quarter 2026 Financial Results on May 6th - geneonline.com
PDS Biotech to give Q1 results and clinical update May 13 - Stock Titan
- SEC.gov
PDS Biotechnology Refinances Debt with New Note, Warrant - TipRanks
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April - MarketBeat
PDSB Stock Price, Quote & Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDSB Stock Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Corporation announced that it expects to receive $5.76 million in funding - marketscreener.com
[EFFECT] PDS Biotechnology Corp SEC Filing - Stock Titan
PDS Biotech 2025 Executive Compensation, Leadership Structure, and Equity Ownership Overview - Minichart
[10-K/A] PDS Biotechnology Corp Amends Annual Report - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) registers $200M shelf, removes $20M ATM - Stock Titan
PDS Biotechnology: FDA-Alignment für VERSATILE-003 - Börse Global
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts - TradingView
PDS Biotech (NASDAQ: PDSB) spotlights PDS0101 Phase 3 and IL-12 ADC - Stock Titan
PDS (PDSB) Stock Analysis: Buy or Sell? | PDS Biotechnology Corporation posts 24.4% EPS beatSocial Buzz Stocks - Xã Thanh Hà
Form DEF 14AOther definitive proxy statements - ADVFN
PDSB: Positive Data from Phase 2 Trial of PDS01ADC Published - GuruFocus
PDSB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15.00 - GuruFocus
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright - MarketBeat
Why Is PDS Biotechnology Stock Gaining Wednesday?PDS Biotechnology (NASDAQ:PDSB) - Benzinga
PDS Biotech’s PDS01ADC Shows 78% Response Rate in Phase 2 Metastatic Colorectal Cancer Trial, Published in JCO Oncology Advances - Minichart
PDS Biotech reports 78% response rate in colorectal cancer trial - Investing.com
PDS Biotech reports 78% response rate in colorectal cancer trial By Investing.com - Investing.com South Africa
Interim PDS01ADC data lift responses in tough mCRC for PDS Biotech (PDSB) - Stock Titan
PDS Biotechnology Announces Promising Phase 2 Trial Results of PDS01ADC for Treatment of Colorectal Liver Metastases - Quiver Quantitative
In a 9-patient colon cancer study, PDS drug showed 78% response - Stock Titan
Aug Drivers: Is PDS Biotechnology Corporation trading at a discount2026 Earnings Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Is PDS (PDSB) Stock Expanding | Price at $1.09, Up 0.93%Trending Social Stocks - Newser
Is PDS (PDSB) Stock Declining | Price at $0.76, Up 19.06%Seasonal Patterns - Newser
What is HC Wainwright’s Estimate for PDSB FY2026 Earnings? - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript - Insider Monkey
PDSB Should I Buy - intellectia.ai
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
PDS Biotechnology Corp 2025 Annual Report: Versamune® Immunotherapy Pipeline, Clinical Results, and Executive Leadership Overview - Minichart
PDS Biotech amends phase 3 trial to speed approval timeline By Investing.com - Investing.com South Africa
PDS Biotech Reports 2025 Financial Results and Advances PDS0101 Phase 3 Program with Accelerated Approval Pathway - Minichart
PDS Biotech (NASDAQ: PDSB) details trial progress and $26.7M cash - Stock Titan
Form 10-K PDS Biotechnology Corp For: Dec 31 - StreetInsider
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap - AlphaStreet
PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings - AlphaStreet
PDSB: Net loss narrowed, clinical trials advanced, and new patents extended exclusivity into the 2040s - TradingView
Bicara Therapeutics 2025 Financial Update - AlphaStreet
Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline - Investing.com
PDS Biotech amends phase 3 trial to speed approval timeline - Investing.com
PDS Biotechnology: Q4 Earnings Snapshot - marketscreener.com
Phase 3 trial shift and cash update for PDS Biotech (NASDAQ: PDSB) - Stock Titan
PDS Biotech Reports Full Year 2025 Financial Results and - GlobeNewswire
PDS Biotechnology FY 2025 earnings preview - MSN
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement - Bitget
Finanzdaten der Pds Biotechnology Corp-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):